

Lewis L Hsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3906847/publications.pdf>

Version: 2024-02-01

124
papers

7,290
citations

81900

39
h-index

56724

83
g-index

128
all docs

128
docs citations

128
times ranked

5376
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. <i>New England Journal of Medicine</i> , 1998, 339, 5-11.	27.0	1,699
2	A Phase 3 Trial of L-Glutamine in Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2018, 379, 226-235.	27.0	378
3	Erythrocytes are the major intravascular storage sites of nitrite in human blood. <i>Blood</i> , 2005, 106, 734-739.	1.4	312
4	Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 665-673.	2.0	291
5	Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. <i>Blood</i> , 2007, 109, 3088-3098.	1.4	241
6	Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. <i>Neurology</i> , 2001, 56, 1109-1111.	1.1	230
7	Stroke Prevention Trial in Sickle Cell Anemia. <i>Contemporary Clinical Trials</i> , 1998, 19, 110-129.	1.9	228
8	Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. <i>Journal of Pediatrics</i> , 2002, 140, 348-354.	1.8	215
9	Sickle cell disease vasculopathy: A state of nitric oxide resistance. <i>Free Radical Biology and Medicine</i> , 2008, 44, 1506-1528.	2.9	208
10	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 727-740.	5.6	197
11	Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 893.	7.4	196
12	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. <i>Blood</i> , 2015, 125, 2656-2664.	1.4	178
13	Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 263-272.	2.0	165
14	Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. <i>Journal of Pediatrics</i> , 2006, 149, 710-712.	1.8	135
15	Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. <i>Blood</i> , 2004, 103, 2822-2826.	1.4	130
16	Silent Infarcts in Children With Sickle Cell Anemia and Abnormal Cerebral Artery Velocity. <i>Archives of Neurology</i> , 2001, 58, 2017.	4.5	112
17	Neurocognitive Functioning and Magnetic Resonance Imaging in Children With Sickle Cell Disease. <i>Journal of Pediatric Psychology</i> , 2000, 25, 503-513.	2.1	111
18	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 441-448.	2.0	111

#	ARTICLE	IF	CITATIONS
19	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. <i>PLoS Medicine</i> , 2017, 14, e1002382.	8.4	107
20	Proinflammatory Cytokines and the Hypermetabolism of Children with Sickle Cell Disease. <i>Experimental Biology and Medicine</i> , 2005, 230, 68-74.	2.4	87
21	Alpha Thalassemia is Associated With Decreased Risk of Abnormal Transcranial Doppler Ultrasonography in Children With Sickle Cell Anemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 622-628.	0.6	85
22	Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. <i>Nature Communications</i> , 2011, 2, 520.	12.8	83
23	Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment. <i>International Journal of Neonatal Screening</i> , 2019, 5, 20.	3.2	80
24	A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex mismatched bone marrow transplantation. <i>Blood</i> , 2002, 99, 1840-1849.	1.4	71
25	Comparison of mechanisms of anemia in mice with sickle cell disease and β^0 -thalassemia. <i>Experimental Hematology</i> , 2002, 30, 394-402.	0.4	68
26	Establishment of a Transgenic Sickle-Cell Mouse Model to Study the Pathophysiology of Priapism. <i>Journal of Sexual Medicine</i> , 2009, 6, 2494-2504.	0.6	64
27	Sickle erythrocyte adherence to endothelium at low shear: Role of shear stress in propagation of vaso-occlusion. <i>American Journal of Hematology</i> , 2002, 70, 216-227.	4.1	59
28	Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2012, 33, 291-297.	1.8	58
29	Community Health Workers as Support for Sickle Cell Care. <i>American Journal of Preventive Medicine</i> , 2016, 51, S87-S98.	3.0	57
30	Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. <i>Blood</i> , 2003, 102, 4582-4593.	1.4	56
31	Enhanced Pulmonary and Systemic Response to Endotoxin in Transgenic Sickle Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 687-695.	5.6	54
32	Sildenafil Citrate-Restored eNOS and PDE5 Regulation in Sickle Cell Mouse Penis Prevents Priapism Via Control of Oxidative/Nitrosative Stress. <i>PLoS ONE</i> , 2013, 8, e68028.	2.5	53
33	The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, E391-E395.	4.1	52
34	Risk-resistance adaptation model for caregivers and their children with sickle cell syndromes. <i>Annals of Behavioral Medicine</i> , 2000, 22, 158-169.	2.9	46
35	IMPROVE trial: A randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. <i>Clinical Trials</i> , 2013, 10, 319-331.	1.6	46
36	Family Functioning and Social Support in the Adaptation of Caregivers of Children With Sickle Cell Syndromes. <i>Journal of Pediatric Psychology</i> , 1998, 23, 377-388.	2.1	45

#	ARTICLE	IF	CITATIONS
37	Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. <i>British Journal of Haematology</i> , 2007, 136, 673-676.	2.5	45
38	Erythropoiesis and Myocardial Energy Requirements Contribute to the Hypermetabolism of Childhood Sickle Cell Anemia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, 680-687.	1.8	43
39	Refining the value of secretory phospholipase A_2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). <i>British Journal of Haematology</i> , 2012, 157, 627-636.	2.5	42
40	Physician-diagnosed asthma and acute chest syndrome: Associations with NOS Polymorphisms. <i>Pediatric Pulmonology</i> , 2007, 42, 332-338.	2.0	39
41	Oxygen Regulates Tissue Nitrite Metabolism. <i>Antioxidants and Redox Signaling</i> , 2012, 17, 951-961.	5.4	39
42	Evidence-Based Interventions Are Necessary but Not Sufficient for Achieving Outcomes in Each Setting in a Complex World. <i>American Journal of Evaluation</i> , 2016, 37, 544-561.	2.1	35
43	Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. <i>British Journal of Haematology</i> , 2011, 155, 263-267.	2.5	34
44	Social Information Processing and Magnetic Resonance Imaging in Children With Sickle Cell Disease. <i>Journal of Pediatric Psychology</i> , 2001, 26, 309-319.	2.1	31
45	C-Reactive Protein and Interleukin-6 Are Decreased in Transgenic Sickle Cell Mice Fed a High Protein Diet. <i>Journal of Nutrition</i> , 2008, 138, 1148-1152.	2.9	29
46	Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: A phase III analgesic trial for hospitalized sickle cell patients with painful episodes. <i>American Journal of Hematology</i> , 2011, 86, E70-E73.	4.1	25
47	Neurodevelopmental Deficits Among Infants and Toddlers with Sickle Cell Disease. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2013, 34, 399-405.	1.1	25
48	The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H4-H7.	3.2	24
49	Comparison of Patients from Nigeria and the USA Highlights Modifiable Risk Factors for Sickle Cell Anemia Complications. <i>Hemoglobin</i> , 2014, 38, 236-243.	0.8	24
50	Parthenolide has limited effects on nuclear factor- κ B increases and worsens survival in lipopolysaccharide-challenged C57BL/6J mice. <i>Cytokine</i> , 2006, 33, 299-308.	3.2	22
51	Ethyl pyruvate decreased early nuclear factor- κ B levels but worsened survival in lipopolysaccharide-challenged mice*. <i>Critical Care Medicine</i> , 2008, 36, 1059-1067.	0.9	22
52	Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: Methodological issues of a randomized controlled trial. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1049-1054.	1.5	22
53	Paediatric to adult transition care for patients with sickle cell disease: a global perspective. <i>Lancet Haematology</i> , 2020, 7, e329-e341.	4.6	22
54	A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2020, 76, S64-S72.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Post-Translational Inactivation of Endothelial Nitric Oxide Synthase in the Transgenic Sickle Cell Mouse Penis. <i>Journal of Sexual Medicine</i> , 2011, 8, 419-426.	0.6	21
56	Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation. <i>Journal of Sexual Medicine</i> , 2015, 12, 1878-1885.	0.6	19
57	White Paper: Pathways to Progress in Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa. <i>Journal of Tropical Diseases</i> , 2018, 06, 260.	0.1	19
58	Positive expiratory pressure device acceptance by hospitalized children with sickle cell disease is comparable to incentive spirometry. <i>Respiratory Care</i> , 2005, 50, 624-7.	1.6	19
59	Pathology of "Berkeley" sickle-cell mice includes gallstones and priapism. <i>Blood</i> , 2006, 107, 3414-3415.	1.4	18
60	A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study. <i>American Journal of Hematology</i> , 2018, 93, 1493-1500.	4.1	18
61	An educational symposium for patients with sickle cell disease and their families: Results from surveys of knowledge and factors influencing decisions about hematopoietic stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1946-1951.	1.5	17
62	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. <i>American Journal of Hematology</i> , 2019, 94, 689-696.	4.1	17
63	PERIPHERAL ARTERIAL TONOMOMETRY IN ASSESSING ENDOTHELIAL DYSFUNCTION IN PEDIATRIC SICKLE CELL DISEASE. <i>Pediatric Hematology and Oncology</i> , 2009, 26, 589-596.	0.8	15
64	Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. <i>American Journal of Hematology</i> , 2021, 96, 1396-1406.	4.1	15
65	SB203580, a p38 Inhibitor, Improved Cardiac Function but Worsened Lung Injury and Survival During <i>Escherichia coli</i> Pneumonia in Mice. <i>Journal of Trauma</i> , 2010, 68, 1317-1327.	2.3	14
66	STARBRIGHT World: A Pilot Study of a Home-Based Sickle Cell Psychoeducational Intervention. <i>Children's Health Care</i> , 2006, 35, 321-338.	0.9	13
67	Self-Reported Physical Activity and Exercise Patterns in Children With Sickle Cell Disease. <i>Pediatric Exercise Science</i> , 2017, 29, 388-395.	1.0	13
68	Perspectives of individuals with sickle cell disease on barriers to care. <i>PLoS ONE</i> , 2022, 17, e0265342.	2.5	13
69	Prevention of Stroke by Transfusions in Children with Sickle Cell Anemia. <i>New England Journal of Medicine</i> , 1998, 339, 1477-1478.	27.0	12
70	Murine and Math Models for the Level of Stable Mixed Chimerism to Cure β^0 -Thalassemia by Nonmyeloablative Bone Marrow Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2005, 1054, 423-428.	3.8	12
71	Platelets decline during vaso-occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. <i>American Journal of Hematology</i> , 2015, 90, E228-9.	4.1	12
72	Associations of β^0 -thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. <i>Blood Advances</i> , 2017, 1, 693-698.	5.2	12

#	ARTICLE	IF	CITATIONS
73	Implementation of Complex Interventions. <i>Medical Care</i> , 2021, 59, S344-S354.	2.4	12
74	Fixed low-dose hydroxyurea for the treatment of adults with sickle cell anemia in Nigeria. <i>American Journal of Hematology</i> , 2018, 93, E193.	4.1	11
75	Transgenic HbS Mouse Neutrophils in Increased Susceptibility to Acute Lung Injury. <i>Chest</i> , 1999, 116, 92S.	0.8	10
76	Parents' Assessment of Risk in Sickle Cell Disease Treatment With Hydroxyurea. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 644-650.	0.6	10
77	Design of the patient navigator to Reduce Readmissions (PARtNER) study: A pragmatic clinical effectiveness trial. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100420.	1.1	9
78	COVID-19 and Sickle Cell Disease-Related Deaths Reported in the United States. <i>Public Health Reports</i> , 2022, 137, 234-238.	2.5	8
79	Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2015, 35, 696-700.	2.6	7
80	Program expansion of a day hospital dedicated to manage sickle cell pain. <i>American Journal of Hematology</i> , 2018, 93, E20-E21.	4.1	7
81	Maximum tolerated dose vs fixed low-dose hydroxyurea for treatment of adults with sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, E112-E115.	4.1	7
82	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 776-776.	1.4	7
83	Parent and Guardian Knowledge of Hematopoietic Cell Transplantation as a Treatment Option for Sickle Cell Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 187-193.	0.6	6
84	Opening Pandora's Box. <i>Medical Care</i> , 2021, 59, S336-S343.	2.4	6
85	Utilising the "Getting to Outcomes" Framework in Community Engagement for Development and Implementation of Sickle Cell Disease Newborn Screening in Kaduna State, Nigeria. <i>International Journal of Neonatal Screening</i> , 2018, 4, 33.	3.2	5
86	Comparing Abstract Numerical and Visual Depictions of Risk in Survey of Parental Assessment of Risk in Sickle Cell Hydroxyurea Treatment. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 4-9.	0.6	4
87	Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes. <i>American Journal of Hematology</i> , 2012, 87, E71-4.	4.1	4
88	Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings. <i>F1000Research</i> , 2018, 7, 1407.	1.6	4
89	Summer Camps for Children with Sickle Cell Disease. <i>Ochsner Journal</i> , 2018, 18, 358-363.	1.1	4
90	coreSCD: multi-stakeholder consensus on core outcomes for sickle cell disease clinical trials. <i>BMC Medical Research Methodology</i> , 2021, 21, 219.	3.1	4

#	ARTICLE	IF	CITATIONS
91	RBC Adhesion to Cremaster Endothelium in Mice with Abnormal Hemoglobin is Increased by Topical Endotoxin. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 391-393.	3.8	3
92	Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria. <i>Blood</i> , 2017, 130, 981-981.	1.4	3
93	Assessing the Appropriateness of Medical Care. <i>New England Journal of Medicine</i> , 1998, 339, 1478-1481.	27.0	2
94	Pulmonary Hypertension of Sickle Cell Disease Beyond Classification Constraints. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2881-2882.	2.8	2
95	Clinical Manifestations of Sickle Cell Anemia: Infants and Children. , 2016, , 213-229.		2
96	Timely Care for Sickle Cell. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2017, 43, 113-115.	0.7	2
97	Letter to the Editor: A Quality Improvement Initiative for Pediatric Resident Education in Venous Thromboembolism Risk Assessment in Pediatric Patients. <i>American Journal of Medical Quality</i> , 2020, 35, 359-360.	0.5	2
98	Trends in School Attendance for Low-Income Children with Chronic Health Conditions: Results from a Randomized Controlled Trial. <i>Journal of School Health</i> , 2021, 91, 187-194.	1.6	2
99	Safety of maximal cardiopulmonary exercise testing in individuals with sickle cell disease: a systematic review. <i>British Journal of Sports Medicine</i> , 2022, 56, 764-769.	6.7	2
100	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. <i>Blood</i> , 2013, 122, 2206-2206.	1.4	2
101	An Electronic Teaching Module for Improving Knowledge of Self-Management of Vaso-Occlusive Pain Crises in Patients With Sickle Cell Disease: Pilot Questionnaire Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e13501.	3.7	2
102	Motivators and Barriers to Physical Activity among Youth with Sickle Cell Disease: Brief Review. <i>Children</i> , 2022, 9, 572.	1.5	2
103	Hydroxyurea makes inflammation –just right?. <i>Blood</i> , 2012, 119, 1796-1798.	1.4	1
104	Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 238-240.	5.6	1
105	Influence of single parenthood on cardiopulmonary function in pediatric patients with sickle cell anemia. <i>Blood Advances</i> , 2020, 4, 3311-3314.	5.2	1
106	Improving VTE prophylaxis adherence among hospitalized adolescents using Human-Centered Design. <i>Journal of Patient Safety and Risk Management</i> , 2021, 26, 172-178.	0.6	1
107	Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes. <i>Blood</i> , 2010, 116, 2667-2667.	1.4	1
108	Assessment of Bone Marrow Function in Sickle Cell Anaemia Patients Using Corrected Reticulocyte Counts. <i>Blood</i> , 2015, 126, 4581-4581.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Commentary on "How Postbaccalaureate Career Changer and Traditional Medical Students Differ Academically" Southern Medical Journal, 2019, 112, 617-618.	0.7	1
110	Semi-automated method to measure pneumonia severity in mice through computed tomography (CT) scan analysis. Proceedings of SPIE, 2010, , .	0.8	0
111	Authors'™ response. Journal of the American Dental Association, 2021, 152, 257.	1.5	0
112	Topical Vapocoolant-Associated Vaso-occlusive Event in a 10-year-old with Sickle Cell Disease. Pain Management Nursing, 2021, 22, 631-633.	0.9	0
113	Apolipoprotein A-I Mimetic Peptide and Sickle Vasculopathy: Mouse Model Study of Acute Administration.. Blood, 2009, 114, 1521-1521.	1.4	0
114	Liver Hypoxia and Tissue Injury Are Specific to Sickle Cell Mice in An Experimental Model of Sickle Cell Vaso-Occlusion.. Blood, 2009, 114, 2569-2569.	1.4	0
115	Peripheral Arterial Tonometry in Assessing Endothelial Dysfunction in Pediatric Sickle Cell Disease. IFMBE Proceedings, 2010, , 544-547.	0.3	0
116	Disparities In Pulmonary Complications of Sickle Cell Disease. Blood, 2010, 116, 2645-2645.	1.4	0
117	Nitrite Oxidase Activities of Cytochrome P450 and Mitochondria. Blood, 2011, 118, 5310-5310.	1.4	0
118	Neurdevelopmental Deficits Among 80 Infants and Toddlers with Sickle Cell Disease. Blood, 2011, 118, 174-174.	1.4	0
119	Pain Medication: Time to First Dose in Sickle Cell Acute Care in Two Settings of a Large Urban Hospital. Blood, 2012, 120, 4693-4693.	1.4	0
120	Early Detection of Renal Dysfunction in Pediatric Sickle Cell Patients. Blood, 2012, 120, 1017-1017.	1.4	0
121	A Comparison Of Sickle Cell Anemia Between Patients From Nigeria and The United States. Blood, 2013, 122, 997-997.	1.4	0
122	Impact of a Dedicated Sickle Cell Acute Care Observation Unit on Rate of Hospital Admission for Acute Pain Crisis. Blood, 2015, 126, 4584-4584.	1.4	0
123	A Survey of Resident Physicians' and Nurses' Knowledge of Severity Assessment of Acute Chest Syndrome and Role of Incentive Spirometry in Management. Blood, 2015, 126, 2064-2064.	1.4	0
124	Nitrous Oxide for Dental Procedures in Pediatric Patients with Sickle Cell Disease: A Pilot Study.. Pediatric Dentistry (discontinued), 2021, 43, 481-483.	0.4	0